Search research articles
Contact Us
Filters
Showing results (91-100 of 323) with videos related to
Page
of 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences
Jitra Kriangkum, Brian J Taylor, Steven P Treon, et al.
Blood Advances
|
July 17, 2025
Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenström macroglobulinemia: A pooled analysis
Alberto Guijosa, Andres Ramirez-Gamero, Shayna Sarosiek, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 12, 2013
microRNA aberrations in Waldenström macroglobulinemia
Antonio Sacco, Yong Zhang, Patricia Maiso, et al.
Journal of the American Academy of Dermatology
|
December 25, 2019
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events
Sean Singer, Sally Y Tan, Anna K Dewan, et al.
Ejhaem
|
September 2, 2022
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
Jorge J Castillo, Shayna Sarosiek, Catherine A Flynn, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 26, 2013
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration
Steven P Treon, Christina K Tripsas, Bryan T Ciccarelli, et al.
Haematologica
|
December 5, 2015
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia
Martin F M de Rooij, Annemieke Kuil, Willem Kraan, et al.
British Journal of Haematology
|
May 28, 2011
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
Steven P Treon, Christina Hanzis, Robert J Manning, et al.
Clinical Lymphoma
|
March 30, 2005
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia
Sophia Adamia, Steven P Treon, Tony Reiman, et al.
Leukemia & Lymphoma
|
August 27, 2016
Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Page
of 33
Search research articles
Search
Showing results (91-100 of 323) with videos related to
Sort By:
Page
of 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences
Jitra Kriangkum, Brian J Taylor, Steven P Treon, et al.
Blood Advances
|
July 17, 2025
Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenström macroglobulinemia: A pooled analysis
Alberto Guijosa, Andres Ramirez-Gamero, Shayna Sarosiek, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 12, 2013
microRNA aberrations in Waldenström macroglobulinemia
Antonio Sacco, Yong Zhang, Patricia Maiso, et al.
Journal of the American Academy of Dermatology
|
December 25, 2019
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events
Sean Singer, Sally Y Tan, Anna K Dewan, et al.
Ejhaem
|
September 2, 2022
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
Jorge J Castillo, Shayna Sarosiek, Catherine A Flynn, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 26, 2013
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration
Steven P Treon, Christina K Tripsas, Bryan T Ciccarelli, et al.
Haematologica
|
December 5, 2015
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia
Martin F M de Rooij, Annemieke Kuil, Willem Kraan, et al.
British Journal of Haematology
|
May 28, 2011
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
Steven P Treon, Christina Hanzis, Robert J Manning, et al.
Clinical Lymphoma
|
March 30, 2005
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia
Sophia Adamia, Steven P Treon, Tony Reiman, et al.
Leukemia & Lymphoma
|
August 27, 2016
Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Page
of 33